A chromatographic method for the quantification of prostaglandin E(1) and prostaglandin A(1) encapsulated in an intravenous lipid formulation.
Peripheral vascular disease is a common ailment of the aged and diabetic communities. As the numbers of these individuals increase, the need for therapeutic interventions will continue to grow. One of the possible therapies is the use of prostaglandins (PGE(1), prostacyclin and Iloprost) to decrease the vascular tone and increase vascular blood flow. Due to the hydrophobicity of the prostaglandins and prostaglandin analogues, various vehicles have been utilized to maintain the active pharmaceutical ingredient in a stable solution, e.g. alpha-cyclodextrin (Alprostadil, Edex) or emulsified lipid vehicles. In our laboratory, we designed a method for separating and assaying lipid-encapsulated PGE(1). Utilizing organic extraction, automated solid-phase extraction and precipitation techniques, we validated the measurement of the PGE(1) and PGA(1) content of the clinical drug formulation in the microgram per milliliter concentration range with an high performance liquid chromatography (HPLC) assay.
Glidden
Paul F
PF
Alpha Therapeutic Corporation, 1213 John Reed Court, City of Industry, CA 91745, USA.
Goldberg
David B
DB
Heldebrant
Charles M
CM
D000527:Alprostadil / Q000008:administration & dosage / Q000032:analysis*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000032:analysis*; D001322:Autoanalysis; D002021:Buffers; D002851:Chromatography, High Pressure Liquid; D007275:Injections, Intravenous; D008081:Liposomes; D011454:Prostaglandins A / Q000008:administration & dosage / Q000032:analysis*; D012015:Reference Standards; D015203:Reproducibility of Results; D012997:Solvents; D013056:Spectrophotometry, Ultraviolet
D000998:Antiviral Agents; D002021:Buffers; D008081:Liposomes; D011454:Prostaglandins A; D012997:Solvents; D000527:Alprostadil; C100573:prostaglandin A1